Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and Retinoic acids

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Han, Shaoteng ^a,c   Fukazawa, Takuya ^b   Yamatsuji, Tomoki ^b   Matsuoka, Junji ^a   Miyachi, Hiroyuki ^a   Maeda, Yutaka ^d   Durbin, Mary ^e   Naomoto, Yoshio ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c CHINA MEDICAL UNIVERSITY   (China)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 (4 PYRIDIN 4 YL)BENZYL 1 OXOISOINDOLIN 6 YL] N HYDROXYACRYLAMIDE; 3 [2 (4 QUINOLIN 3 YL)BENZYL 1 OXOISOINDOLIN 6 YL] N HYDROXYACRYLAMIDE; ALITRETINOIN; CASPASE 3; HISTONE; HISTONE DEACETYLASE INHIBITOR; LUCIFERASE; PROTEIN BAX; PROTEIN P21; PROTEIN P27; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; SL 142; SL 325; UNCLASSIFIED DRUG; VORINOSTAT; 3 (2 (4 PYRIDIN 4 YL)BENZYL 1 OXOISOINDOLIN 6 YL) N HYDROXYACRYLAMIDE; 3 (2 (4 QUINOLIN 3 YL)BENZYL 1 OXOISOINDOLIN 6 YL) N HYDROXY ACRYLAMIDE; 3-(2-(4-PYRIDIN-4-YL)BENZYL-1-OXOISOINDOLIN-6-YL)-N-HYDROXYACRYLAMIDE; 3-(2-(4-QUINOLIN-3-YL)BENZYL-1-OXOISOINDOLIN-6-YL)-N-HYDROXY-ACRYLAMIDE; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; HYDROXAMIC ACID; ISOINDOLE DERIVATIVE; RETINOIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DNA CONTENT; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG CANCER; MONOTHERAPY; PROTEIN EXPRESSION; TANDEM REPEAT; TRANSCRIPTION REGULATION; ACETYLATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DNA RESPONSIVE ELEMENT; GENETIC TRANSCRIPTION; GENETICS; IMMUNOBLOTTING; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACETYLATION; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; IMMUNOBLOTTING; ISOINDOLES; LUNG NEOPLASMS; MOLECULAR STRUCTURE; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC; TRETINOIN;

EID: 78149491383     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013834     Document Type: Article

References (71)

1. Struhl K (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12: 599-606.
2. Rosato RR, Grant S (2003) Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2: 30-37.
3. Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, et al. (1996) p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12: 1565-1569.
4. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, et al. (1998) Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 18: 126-135.
5. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, et al. (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815-818.
6. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Jr., et al. (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391: 811-814.
7. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216.
8. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoterassociated proteins, including HDAC1. Proc Natl Acad Sci U S A 101: 1241-1246.
9. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
10. Boehm MF, McClurg MR, Pathirana C, Mangelsdorf D, White SK, et al. (1994) Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties. J Med Chem 37: 408-414.
11. Picard E, Seguin C, Monhoven N, Rochette-Egly C, Siat J, et al. (1999) Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J Natl Cancer Inst 91: 1059-1066.
12. Brabender J, Danenberg KD, Metzger R, Schneider PM, Lord RV, et al. (2002) The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer. Clin Cancer Res 8: 438-443.
13. Brabender J, Metzger R, Salonga D, Danenberg KD, Danenberg PV, et al. (2005) Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: implications for tumor development and prognosis. Carcinogenesis 26: 525-530.
14. Aranda A, Pascual A (2001) Nuclear hormone receptors and gene expression. Physiol Rev 81: 1269-1304.
15. Coffey DC, Kutko MC, Glick RD, Swendeman SL, Butler L, et al. (2000) Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 35: 577-581.
16. De los Santos M, Zambrano A, Aranda A (2007) Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol Cancer Ther 6: 1425-1432.
17. Shinji C, Maeda S, Imai K, Yoshida M, Hashimoto Y, et al. (2006) Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors. Bioorg Med Chem 14: 7625-7651.
18. Miyachi H, Kato M, Kato F, Hashimoto Y (1998) Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton. J Med Chem 41: 263-265.
19. Shinji C, Nakamura T, Maeda S, Yoshida M, Hashimoto Y, et al. (2005) Design and synthesis of phthalimide-type histone deacetylase inhibitors. Bioorg Med Chem Lett 15: 4427-4431.
20. de The H, Vivanco-Ruiz MM, Tiollais P, Stunnenberg H, Dejean A (1990) Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. Nature 343: 177-180.
21. de The H, Lavau C, Marchio A, Chomienne C, Degos L, et al. (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66: 675-684.
22. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97: 10014-10019.
23. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359: 1367-1380.
24. Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler G (2007) A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol 2: 1091-1097.
25. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
26. Horn L, Pao W (2009) EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27: 4232-4235.
27. Hoang T, Traynor AM, Schiller JH (2002) Novel therapies for lung cancer. Surg Oncol 11: 229-241.
28. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299.
29. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, et al. (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202.
30. Monneret C (2007) Histone deacetylase inhibitors for epigenetic therapy of cancer. Anticancer Drugs 18: 363-370.
31. Monneret C (2005) Histone deacetylase inhibitors. Eur J Med Chem 40: 1-13.
32. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
33. Kelly WK, Marks PA (2005) Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150-157.
34. Parmigiani RB, Xu WS, Venta-Perez G, Erdjument-Bromage H, Yaneva M, et al. (2008) HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A 105: 9633-9638.
35. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
36. Zhang XH, Rao M, Loprieato JA, Hong JA, Zhao M, et al. (2008) Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther 7: 1388-1397.
37. Imre G, Gekeler V, Leja A, Beckers T, Boehm M (2006) Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 66: 5409-5418.
38. Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, et al. (2006) SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 15: 187-191.
39. Chambon P (1994) The retinoid signaling pathway: molecular and genetic analyses. Semin Cell Biol 5: 115-125.
40. Pfahl M (1994) Vertebrate receptors: molecular biology, dimerization and response elements. Semin Cell Biol 5: 95-103.
41. Jetten AM, Nervi C, Vollberg TM (1992) Control of squamous differentiation in tracheobronchial and epidermal epithelial cells: role of retinoids. J Natl Cancer Inst Monogr. pp 93-100.
42. Kelloff GJ, Boone CW, Steele VK, Perloff M, Crowell J, et al. (1993) Development of chemopreventive agents for lung and upper aerodigestive tract cancers. J Cell Biochem Suppl 17F: 2-17.
43. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, et al. (1993) Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11: 1216-1222.
44. Hoffman AD, Engelstein D, Bogenrieder T, Papandreou CN, Steckelman E, et al. (1996) Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cisretinoic acid. Clin Cancer Res 2: 1077-1082.
45. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, et al. (2001) Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61: 2-7.
46. Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, et al. (2005) Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 11: 3535-3542.
47. Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, et al. (2007) Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 6: 70-81.
48. Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, et al. (2007) A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A 104: 17777-17782.
49. Hall RK, Scott DK, Noisin EL, Lucas PC, Granner DK (1992) Activation of the phosphoenolpyruvate carboxykinase gene retinoic acid response element is dependent on a retinoic acid receptor/coregulator complex. Mol Cell Biol 12: 5527-5535.
50. Husmann M, Hoffmann B, Stump DG, Chytil F, Pfahl M (1992) A retinoic acid response element from the rat CRBPI promoter is activated by an RAR/RXR heterodimer. Biochem Biophys Res Commun 187: 1558-1564.
51. Giannini F, Maestro R, Vukosavljevic T, Pomponi F, Boiocchi M (1997) Alltrans, 13-cis and 9-cis retinoic acids induce a fully reversible growth inhibition in HNSCC cell lines: implications for in vivo retinoic acid use. Int J Cancer 70: 194-200.
52. Joung KE, Min KN, An JY, Kim DK, Kong G, et al. (2006) Potent in vivo antibreast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice. Cancer Res 66: 5394-5402.
53. Eck-Enriquez K, Kiefer TL, Spriggs LL, Hill SM (2000) Pathways through which a regimen of melatonin and retinoic acid induces apoptosis in MCF-7 human breast cancer cells. Breast Cancer Res Treat 61: 229-239.
54. Nagpal S (2004) Retinoids: inducers of tumor/growth suppressors. J Invest Dermatol 123: xx, xxi.
55. Orlandi A, Bianchi L, Costanzo A, Campione E, Giusto Spagnoli L, et al. (2004) Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. J Invest Dermatol 122: 1037-1041.
56. Pettersson F, Dalgleish AG, Bissonnette RP, Colston KW (2002) Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br J Cancer 87: 555-561.
57. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, et al. (2007) Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 121: 656-665.
58. Lavelle D, Chen YH, Hankewych M, DeSimone J (2001) Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 68: 170-178.
59. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, et al. (1998) Role of PML in cell growth and the retinoic acid pathway. Science 279: 1547-1551.
60. Weber E, Ravi RK, Knudsen ES, Williams JR, Dillehay LE, et al. (1999) Retinoic acid-mediated growth inhibition of small cell lung cancer cells is associated with reduced myc and increased p27Kip1 expression. Int J Cancer 80: 935-943.
61. Zhang H, Rosdahl I (2004) Expression profiles of p53, p21, bax and bcl-2 proteins in all-trans-retinoic acid treated primary and metastatic melanoma cells. Int J Oncol 25: 303-308.
62. Liu M, Iavarone A, Freedman LP (1996) Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J Biol Chem 271: 31723-31728.
63. Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163.
64. Levkau B, Koyama H, Raines EW, Clurman BE, Herren B, et al. (1998) Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1: 553-563.
65. Steinman RA, Johnson DE (2000) p21WAF1 prevents down-modulation of the apoptotic inhibitor protein c-IAP1 and inhibits leukemic apoptosis. Mol Med 6: 736-749.
66. Javelaud D, Besancon F (2002) Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio. J Biol Chem 277: 37949-37954.
67. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, et al. (1998) Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 95: 4997-5002.
68. Roth W, Reed JC (2002) Apoptosis and cancer: when BAX is TRAILing away. Nat Med 8: 216-218.
69. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299.
70. Mitchell CE, Belinsky SA, Lechner JF (1995) Detection and quantitation of mutant K-ras codon 12 restriction fragments by capillary electrophoresis. Anal Biochem 224: 148-153.
71. Zhang YA, Nemunaitis J, Scanlon KJ, Tong AW (2000) Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. Gene Ther 7: 2041-2050.